Skip to main content

Zevra Therapeutics, Inc.

ZVRA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001434647

In the last 90 days, Zevra Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $642.0M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Zevra Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
2 filings
2 insiders, $613.2K in total
Insiders trading
2
Net value
−$613.2K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Zevra Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Zevra Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Thompson RahsaanChief Legal & Compliance37,569Aug 17, 20264
Watton Corey MichaelDirector1,800Aug 12, 20262
Seymour Tamara ADirector3,894Jun 18, 20261
Calder Douglas WDirector–Jun 18, 20261
Secor AliciaDirector–Jun 18, 20262
Shih AlvinDirector20,000Jun 18, 20261
Anderson ThomasDirector20,000Jun 18, 20261
Sangiovanni Timothy J.SVP, Finance & Corp Controller29,590May 29, 20263
Bode John BDirector123,400Mar 26, 20261
Renz Justin ACFO–Mar 19, 20261
McFarlane Neil F.President and CEO387,225Feb 10, 20263
Schafer JoshuaCCO62,278Feb 4, 20262
Quartel Adrian WChief Medical Officer9,723Feb 2, 20261
Clifton R. LaDuaneOther: Former CFO & Treasurer143,515Jan 7, 20261
Dixon Wendy LDirector–May 30, 20250
Mickle Christal M MChief Development Officer–Feb 2, 20240
Guenther SvenChief Scientific Officer–Feb 2, 20240
Saluri JosephDirector–May 8, 20230
Plooster Matthew RDirector18,500May 8, 20230
Tierney David SDirector10,835Mar 13, 20230
Pascoe Richard WChief Executive Officer29,973Mar 13, 20230
Mickle Travis CPresident & CEO11,034IndirectMay 25, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
May 24, 2022 (view filing)May 204 daysSeymour Tamara ADirectorPPurchase+200$4.87+$974New position200 after
May 18, 2022 (view filing)May 18Same dayPlooster Matthew RDirectorPPurchase+5.00K$4.96+$24.8K+200.0%7.50K after4 lots
May 18, 2022 (view filing)May 18Same dayPascoe Richard WExecutive ChairmanPPurchase+5.00K$4.92+$24.6K+152.2%8.29K after7 lots
May 18, 2022 (view filing)May 18Same dayClifton R. LaDuaneCFO, Secretary & TreasurerPPurchase+1.20K$5.00+$6.00K+22.9%6.44K after
Nov 30, 2021 (view filing)Nov 30Same dayPascoe Richard WExecutive ChairmanPPurchase+1.50K$7.88+$11.8K+84.0%3.29K after
Nov 30, 2021 (view filing)Nov 30Same dayTierney David SDirectorPPurchase+2.00K$7.79+$15.6K+109.0%3.83K after
Nov 23, 2021 (view filing)Nov 185 daysLateMickle Travis CPresident & CEOPPurchase+2.25K$8.23+$18.5K+6.6%36.5K after
Nov 18, 2021 (view filing)Nov 18Same dayClifton R. LaDuaneCFO, Secretary & TreasurerPPurchase+510$8.29+$4.23K+10.8%5.24K after
Sep 29, 2021 (view filing)Sep 29Same dayClifton R. LaDuaneCFO, Secretary & TreasurerPPurchase+215$9.38+$2.02K+4.8%4.73K after
Sep 20, 2021 (view filing)Sep 20Same dayClifton R. LaDuaneCFO, Secretary & TreasurerPPurchase+935$8.59+$8.03K+26.1%4.51K after
Sep 1, 2021 (view filing)Sep 1Same dayClifton R. LaDuaneCFO, Secretary & TreasurerPPurchase+230$9.11+$2.10K+6.9%3.58K after
Aug 30, 2021 (view filing)Aug 30Same dayMickle Travis CPresident & CEOPPurchase+5.00K$8.92+$44.6K+17.1%34.3K after